These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. [Immune response of HBsAg gene-modified dendritic cell-based vaccine in HepG2. 2. 15 hepatocellular carcinoma cells]. Yang JY; Liu WC; Cao DY; Si XM; Teng ZH Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):728-32. PubMed ID: 18396682 [TBL] [Abstract][Full Text] [Related]
44. Induction of tumor immunity and cytotoxic t lymphocyte responses using dendritic cells transduced by adenoviral vectors encoding HBsAg: comparison to protein immunization. Qiu SJ; Lu L; Qiao C; Wang L; Wang Z; Xiao X; Qian S; Fung JJ; Ye SL; Bonham CA J Cancer Res Clin Oncol; 2005 Jul; 131(7):429-38. PubMed ID: 15818505 [TBL] [Abstract][Full Text] [Related]
45. Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes. Strobel I; Berchtold S; Götze A; Schulze U; Schuler G; Steinkasserer A Gene Ther; 2000 Dec; 7(23):2028-35. PubMed ID: 11175315 [TBL] [Abstract][Full Text] [Related]
46. Feasibility of CTLA4Ig gene delivery and expression in vivo using retrovirally transduced myeloid dendritic cells that induce alloantigen-specific T cell anergy in vitro. Takayama T; Morelli AE; Robbins PD; Tahara H; Thomson AW Gene Ther; 2000 Aug; 7(15):1265-73. PubMed ID: 10918497 [TBL] [Abstract][Full Text] [Related]
47. Electroporation of dendritic cells with autologous total RNA from tumor material. Milano F; Krishnadath KK Methods Mol Biol; 2014; 1139():87-95. PubMed ID: 24619673 [TBL] [Abstract][Full Text] [Related]
48. Electroporation as a method of choice to generate genetically modified dendritic cell cancer vaccines. Ahmed R; Sayegh N; Graciotti M; Kandalaft LE Curr Opin Biotechnol; 2020 Oct; 65():142-155. PubMed ID: 32240923 [TBL] [Abstract][Full Text] [Related]